Skip to main content

Peer Review reports

From: Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial

Original Submission
23 Jul 2018 Submitted Original manuscript
16 Aug 2018 Author responded Author comments - Florian Eichhorn
Resubmission - Version 2
16 Aug 2018 Submitted Manuscript version 2
16 Oct 2018 Reviewed Reviewer Report - Andreas Pircher
15 Nov 2018 Reviewed Reviewer Report - Reviewer 2
19 Dec 2018 Author responded Author comments - Florian Eichhorn
Resubmission - Version 3
19 Dec 2018 Submitted Manuscript version 3
25 Jan 2019 Reviewed Reviewer Report - Reviewer 2
12 Apr 2019 Author responded Author comments - Florian Eichhorn
Resubmission - Version 4
12 Apr 2019 Submitted Manuscript version 4
Publishing
18 Apr 2019 Editorially accepted
2 May 2019 Article published 10.1186/s12885-019-5624-2

You can find further information about peer review here.

Back to article page